| Vol. 9.36 – 22 September, 2021 |
| |
|
|
| Immunoglobulin G from mRNA-immunized nonhuman primates was passively transferred in a highly pathogenic Syrian hamster SARS-CoV-2 challenge model to determine whether these antibodies were sufficient for protection. [Science] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis on anti-CD20 antibody monotherapy compared with healthy controls after BNT162b2 or mRNA-1273 mRNA vaccination. [Nature Medicine] |
|
|
|
| Investigators found that viral infection promoted the G protein–coupled receptor lysophosphatidic acid (LPA)1 expression, and LPA restrained type I/III interferon production through LPA1. [Science Advances] |
|
|
|
| Researchers showed that critical COVID-19 was associated with enhanced eosinophil-mediated inflammation when compared to non-critical cases. [Cell Reports] |
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists designed a series of peptides specifically targeting enterovirus A71-encoded protein 3A, a viral suppressor of RNAi. The peptides showed in vitro and in vivo anti-enteroviral efficacy that depends on RNAi. [Immunity] |
|
|
|
| The authors found the chlamydial parasitophorous vacuole protein CT135 triggered NLRP3 inflammasome activation via TLR2/MyD88 signaling as a pathogenic strategy to evade neutrophil host defense. [Nature Communications] |
|
|
|
| Investigators developed an HIV-1 promoter-targeting Zinc Finger Protein fused to active domains of DNA methyltransferase 3 A to induce long-term stable epigenetic repression of HIV-1. [Nature Communications] |
|
|
|
| Scientists demonstrated that a characteristic additional third nuclear factor κB binding site in the long terminal repeat promoter allows subtype C HIV-1 strains to evade restriction by nuclear PYHIN proteins. [Cell Reports] |
|
|
|
| The authors found that topoisomerase-II was a substrate of the Epstein-Barr virus ubiquitin deconjugase BPLF1. [PLOS Pathogens] |
|
|
|
| Researchers reported that CXCR3-dependent recruitment of Ly6C+ Th1 effector cells was indispensable for concomitant immunity and acute cell-phagocyte interactions were critical to prevent the establishment of a permissive pathogen niche. [PLOS Pathogens] |
|
|
|
|
| The authors delineate the structural features of SARS-CoV-2 from the whole viral particle to the individual viral proteins and discuss their functions as well as their potential as targets for therapeutic interventions. [Nature Reviews Microbiology] |
|
|
|
| Scientists describe chemical signaling systems in E. coli in the context of the broader field of metabolism at the host–bacteria interface and the role of this signaling in disease modulation. [Nature Chemical Biology] |
|
|
|
|
| The Vaccine and Infectious Disease Organization, known as VIDO, at the University of Saskatchewan is moving to Phase II of clinical testing of a COVID-19 vaccine developed at its lab in Saskatoon. VIDO (GlobalNews, Inc.) |
|
|
|
| City of Hope is now enrolling patients in a Phase II clinical trial of its COH04S1 vaccine that is the first to study the safety and effectiveness of an investigational vaccine in blood cancer patients who have received a bone marrow transplant or CAR T therapy. [City of Hope (BusinessWire, Inc.)] |
|
|
|
|
| January 12 – 14, 2022 Shanghai, China |
|
|
|
|
|
| University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| Vanderbilt University Medical Center – Nashville, Tennessee, United States |
|
|
|
| University of Gothenburg – Gothenburg, Sweden |
|
|
|
| University of Colorado – Aurora, Colorado, United States |
|
|
|
| Cleveland Clinic – Port Saint Lucie, Florida, United States |
|
|
|
|